In a groundbreaking advance against obesity and diabetes, researchers have unveiled a novel quintuple agonist that simultaneously targets GLP-1R, GIPR, and PPAR α/γ/δ receptors with unparalleled efficacy in preclinical models. This innovative compound, GLP-1–GIP–Lani, not only reduces body weight and fat mass dramatically but also enhances metabolic parameters, hepatic health, and cardiovascular function beyond existing therapeutic combinations, heralding a new paradigm in polypharmacology for complex metabolic diseases.
Obesity and type 2 diabetes remain global health crises, burdening healthcare systems with escalating morbidity and mortality. Therapeutic strategies historically focused on single hormonal pathways, such as GLP-1 receptor agonists, have shown promise but often lack comprehensive metabolic control and cardiometabolic benefits. The development of multi-receptor agonists, including dual agonism of GLP-1R and GIPR, marked significant progress; however, significant unmet needs persist, particularly in overcoming obesity resistance and attenuating associated organ damage.
The recent preclinical study evaluated GLP-1–GIP–Lani, a conjugate peptide agonist that fuses dual incretin receptor activity with pan-PPAR targeting, in diet-induced obese (DIO) mice. This compound was administered daily via subcutaneous injection over an extended period. Striking weight loss was observed—surpassing that induced by co-administration of GLP-1–GIP with the PPAR-activating peptide lanifibranor. Importantly, weight reduction primarily stemmed from decreases in fat mass, while lean tissue mass was preserved, indicating selective adipose tissue targeting without muscle degradation.
Beyond weight management, GLP-1–GIP–Lani improved glucose homeostasis with superior glucose tolerance and insulin sensitivity relative to both vehicle controls and the comparator treatments. Consistent decreases in fasting blood glucose and plasma insulin concentrations highlighted its potent antihyperglycemic effects. These results underscore the compound’s ability to modulate pancreatic β-cell function and systemic insulin responsiveness effectively, crucial for halting diabetes progression.
Hepatic measurements revealed compelling benefits. GLP-1–GIP–Lani reduced liver weight and markedly diminished hepatic triglyceride accumulation, a hallmark of non-alcoholic fatty liver disease frequently accompanying obesity and diabetes. Biochemical liver injury markers, including plasma aspartate aminotransferase and alanine aminotransferase, were also reduced, suggesting hepatoprotective properties. Histological assessments confirmed the absence of adverse tissue alterations across the liver, skeletal muscle, heart, adipose tissue, and kidney, indicating a favorable safety profile.
Cardiac outcomes further distinguished GLP-1–GIP–Lani. In DIO mice, the quintuple agonist mitigated diet-induced cardiac hypertrophy, a condition contributing to heart failure risk. Functional cardiac parameters improved significantly, with increases in ejection fraction, fractional shortening, stroke volume, and cardiac output noted, coupled with a reduction in heart rate—all without deleterious changes in systemic blood pressure. This suggests enhanced cardiac efficiency and workload management in metabolically compromised states.
Renal safety, a critical consideration for metabolic drugs, was rigorously assessed. GLP-1–GIP–Lani administration did not provoke anemia, fluid retention, or alterations in creatinine concentrations in plasma or urine, indicating preserved renal function. These findings alleviate concerns about potential off-target renal side effects that have hampered the clinical translation of some metabolic agents.
A particularly striking finding was the compound’s efficacy in leptin receptor-deficient db/db mice, an obesity-prone model notoriously resistant to weight loss interventions including established drugs like tirzepatide and semaglutide. GLP-1–GIP–Lani fully prevented body weight gain and significantly outperformed the GLP-1–GIP plus lanifibranor co-treatment in reducing fat mass and food intake without lean mass compromise. Enhanced glucose regulation further validated its applicability in severe genetic obesity contexts.
This multifaceted therapeutic effect stems from the strategic polypharmacological approach that simultaneously manipulates incretin signaling and nuclear receptor pathways. GLP-1 and GIP receptor activation synergizes to optimize insulin secretion and appetite suppression, while pan-PPAR agonism modulates lipid metabolism, energy expenditure, and inflammation. This integrative mechanism addresses the complex pathophysiology of metabolic syndrome more effectively than receptor-selective agents.
The findings carry significant translational implications. GLP-1–GIP–Lani’s unique ability to induce sustained weight loss alongside robust glycemic control and organ protection without compromising lean mass or renal function may revolutionize treatment algorithms for obesity and type 2 diabetes. Future clinical studies will be pivotal to ascertain its safety and efficacy in humans, but the preclinical evidence offers a compelling rationale for rapid advancement.
Moreover, this study exemplifies the therapeutic promise of designing multifunctional agonists that integrate complementary receptor activities to overcome resistance mechanisms and enhance metabolic resilience. Such strategies hold potential not only for metabolic diseases but also for other complex disorders requiring concerted modulation of multiple pathways.
In conclusion, GLP-1–GIP–Lani epitomizes a next-generation polyagonist therapy that corrects obesity and diabetes in mouse models with exceptional potency and safety. By fostering weight loss, improving glucose metabolism, safeguarding liver function, enhancing cardiac performance, and preserving renal health, this quintuple agonist advances the frontier of metabolic therapeutics and offers hope for more effective clinical interventions.
Subject of Research:
Development and evaluation of a multi-receptor agonist (GLP-1R–GIPR–PPARα/γ/δ) for treating obesity and diabetes in mouse models.
Article Title:
GLP-1R–GIPR–PPARα/γ/δ quintuple agonism corrects obesity and diabetes in mice.
Article References:
Liskiewicz, D., Novikoff, A., Khalil, A. et al. GLP-1R–GIPR–PPARα/γ/δ quintuple agonism corrects obesity and diabetes in mice. Nature (2026). https://doi.org/10.1038/s41586-026-10427-5
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41586-026-10427-5
Tags: cardiometabolic health improvementcombined incretin and PPAR activationfat mass reduction mechanismsGLP-1–GIP–Lani peptide therapyGLP-1R GIPR PPAR agonismlanifibranor and incretin receptor synergymulti-receptor targeting in metabolic diseasenovel obesity therapeutics in miceobesity resistance overcoming strategiespolypharmacology in diabetes managementpreclinical metabolic disease modelsquintuple agonist for obesity treatment
